Overview

A Pilot Study of a New MiraLax® Dose Formulation For Use in Constipated Children

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate patient acceptance of a new MiraLax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.
Phase:
Phase 4
Details
Lead Sponsor:
Braintree Laboratories
Treatments:
Polyethylene glycol 3350